Chief Physician, Doctoral Supervisor, Chief Expert of Pediatric CAR-T
Affiliated HospitalInstitute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)
→
Research areas : T-cell acute lymphoblastic leukemia, gene-edited CAR-T; Cutting-edge technologies: Internationally pioneering donor-derived CDCAR-T, CD19/CD22 sequential CAR-T; Diseases of expertise: Relapsed/refractory T-ALL, B-ALL; Academic highlights: Results published in Lancet Oncol and J Clin Oncol, and included in guidelines of multiple countries; Core value: Overcoming the bottleneck of CAR-T therapy for T-cell leukemia and solving the problem of antigen escape relapse.
Pan Jing
Chief Physician, Doctoral Supervisor, Chief Expert of Pediatric CAR-T
Research areas : T-cell acute lymphoblastic leukemia, gene-edited CAR-T; Cutting-edge technologies: the world's first donor-derived CDCAR-T, CD19/CD22 sequential CAR-T;
Diseases specializing in: Relapsed and refractory T-ALL and B-ALL; Academic highlights: Research findings published in Lancet Oncol and J Clin Oncol, and included in guidelines of multiple countries; Core value: Overcoming the bottleneck of CAR-T therapy for T-cell leukemia and solving the problem of antigen escape relapse.